Research Analysts’ Weekly Ratings Updates for Shattuck Labs (STTK)

Shattuck Labs (NASDAQ: STTK) recently received a number of ratings updates from brokerages and research firms:

• 6/13/2026 – Shattuck Labs was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/8/2026 – Shattuck Labs had its price target raised by Needham & Company LLC from $14.00 to $17.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Shattuck Labs had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 6/5/2026 – Shattuck Labs was upgraded by Jefferies Financial Group Inc. to “outperform”. They now have a $7.00 price target on the stock.
• 6/5/2026 – Shattuck Labs was upgraded by Citigroup Inc. from “neutral” to “buy”. They now have a $7.00 price target on the stock.
• 6/2/2026 – Shattuck Labs was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/23/2026 – Shattuck Labs was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/19/2026 – Shattuck Labs was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/8/2026 – Shattuck Labs had its price target raised by Wedbush from $8.00 to $11.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – Shattuck Labs is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 4/20/2026 – Shattuck Labs had its price target raised by HC Wainwright from $6.00 to $18.00. They now have a “buy” rating on the stock.

Insider Transactions at Shattuck Labs

In other news, Director Clay B. Siegall purchased 62,500 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were bought at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the completion of the acquisition, the director directly owned 318,608 shares in the company, valued at approximately $1,274,432. This trade represents a 24.40% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arundathy N. Pandite sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total value of $198,300.00. Following the completion of the sale, the insider owned 166,219 shares in the company, valued at approximately $1,098,707.59. This trade represents a 15.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 8.79% of the company’s stock.

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.